The outlook of companies tied to the drug's past presents a intricate investment scenario . While the initial success generated substantial returns , generic alternatives have significantly impacted revenue. Investing in connected pharmaceutical businesses now requires a discerning assessment of patent protection , evolving medical shifts , and the